Market Research Report
Europe Sleep Apnea Therapeutics and Diagnostics Market Forecast 2021-2028
|Published by||Inkwood Research||Product code||1018667|
|Published||Content info||161 Pages
Delivery time: 2-3 business days
|Europe Sleep Apnea Therapeutics and Diagnostics Market Forecast 2021-2028|
|Published: July 19, 2021||Content info: 161 Pages||
The Europe sleep apnea therapeutics and diagnostics market is estimated to project a CAGR of 6.48% during the forecast period, 2021-2028. The growing demand for PAP devices drives market growth.
The United Kingdom, Poland, Belgium, France, Germany, Italy, Russia, and Rest of Europe, are assessed for the Europe sleep apnea therapeutics and diagnostics market growth analysis. Italy has a high prevalence of sleep apnea. The growing use of oral appliances for sleep apnea treatment and beneficial reimbursement policies propel market growth. The usage of custom-made oral appliances is attributed to the lack of medical adherence for sleep apnea. As per an Elsevier study, developing custom-made and titratable oral appliances can minimize the degree of mandibular advancement of the jaw and apneic incidences. Further, during the pandemic, the Italian Respiratory Society (IRS) and the Italian Thoracic Society (ITS) recommend using PAP devices as the second alternative.
In Russia, the pandemic has resulted in increased demands for home sleep solutions, including diagnosis, monitoring, and treatment solutions. Other laboratory services like mask fitting and in-lab titration of PAP devices further offer growth opportunities. As per the Russian Federal State Statistics Service, the incidence rate of CVD was 32.1% per 1000 people in 2018. There is a high prevalence of CVD risk factors like hypertension, diabetes, obesity, and smoking. Such factors can place the population at higher risk of sleep-disordered breathing (SDB).
Some of the leading companies in the market include: Invacare Corporation, Fisher & Paykel Healthcare Corporation Limited, GE Healthcare, Itamar Medical Ltd, Medtronic Plc, etc.